Kyowa Kirin Co Ltd 2014 Annual Report
The report records 2014 consolidated net sales of ¥333,446 million and highlights the launches of G-Lasta® and Dovobet®. It describes ProStrakan's acquisition of Archimedes Pharma and continued global development alliances for KW-0761. Environmental disclosures report 354,000 tons of Group CO2 emissions and a fiscal 2020 target to keep emissions no more than 85% of the fiscal 1990 level. The report also discusses reforms following inappropriate participation in clinical research and Group-wide antibribery measures.
Company: Kyowa Kirin Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2014
Type: Annual Report
Pages: 82
Back to company
Kyowa Kirin Co Ltd
Annual Report
The report records 2014 consolidated net sales of ¥333,446 million and highlights the launches of G-Lasta® and Dovobet®. It describes ProStrakan's acquisition of Archimedes Pharma and continued global development alliances for KW-0761. Environmental disclosures report 354,000 tons of Group CO2 emissions and a fiscal 2020 target to keep emissions no more than 85% of the fiscal 1990 level. The report also discusses reforms following inappropriate participation in clinical research and Group-wide antibribery measures.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Type
Annual Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Employees